Written by Emil Luca: Elypta is a Swedish cancer diagnostics company focused on reducing cancer mortality by enabling earlier detection and closer monitoring.  It aims to commercialize the first metabolism-based liquid biopsy for early cancer detection. The metabolism-based liquid biopsy platform measures a novel panel of glycosaminoglycan biomarkers (GAGome), with algorithms trained to detect cancer-specific signatures.

Glycosaminoglycans (GAGs) are essential structural components of tissue matrix. Their composition differs from one tissue to another. According to the new method of cancer detection, free GAG profile can be an early diagnostic marker of any type of cancer.

Elypta’s MIRAM® Free Glycosaminoglycan Kit leverages established state-of-the-art lab methods for glycosaminoglycan (GAG) extraction and detection to deliver high and reliable performance in a standardized and scalable way. The method relies on an enzymatic digestion assay that depolymerizes GAGs into disaccharides. Disaccharides are subsequently labeled and separated by ultra-high performance liquid chromatography (UHPLC) and detected using electrospray ionization triple-quadrupole mass spectrometry (ESI-MS/MS).

MIRAM® Free Glycosaminoglycan Kits accurately measure the concentration and structural composition of chondroitin sulfate (CS), heparan sulfate (HS), and hyaluronic acid (HA). The measurements can be done in a wide array of research specimens including blood, urine, cell cultures, tissues, and other biofluids. The kit requires only comparatively small sample volumes to produce precise results across the full glycosaminoglycan profile.

The company has succeeded in raising the capital that it will use to develop and validate blood and urine tests for Multi-Cancer Early Detection (MCED). Using the GAGome as biomarkers of cancer metabolism, the company stresses early cancer detection in adults with no symptoms of cancer and detection of recurrence in kidney cancer patients.

This MCED test has the potential to greatly increase the share of cancers detected at the earliest stages when treatment could mean a cure besides being less costly. Whereas other MCED tests based on cell free DNA struggle to find cancer at an early stage, metabolism-based biomarkers could really make a difference.

This new test is another addition to the tests for early cancer detection and diagnosis. It is another step towards the control of cancer and curbing its grave health and economic burden. Early diagnosis and personalized therapy are now the keys towards this goal.

What is Liquid Biopsy?

Cancer Blood Tests Revolutionize Oncology

What is metabolome?

The writer declares no conflict of interest. Specific information about this product are obtained from the manufacturer’s website. Inquiries are to be addressed to the manufacturer.

See All Products